Sousa Tercia Tarciane, Santos Bruna do Nascimento, Belotto Marcos, Peixoto Renata D'Alpino
Department of Oncology, São José Hospital, São Paulo/SP, Brazil.
Medical student, Santa Casa de São Paulo Medical School, São Paulo/SP, Brazil.
J Gastrointest Oncol. 2016 Dec;7(6):E103-E106. doi: 10.21037/jgo.2016.11.06.
Despite rare, metastatic anal carcinoma confers a poor prognosis. Systemic chemotherapy is the mainstay of treatment for advanced disease while the role of biologics and/or surgical resection of metastatic disease are anecdotal. Compared to isolated liver colorectal or neuroendocrine cancer liver metastases, there is far less experience with resection or nonsurgical local ablative procedures for patients with metastatic anal carcinoma to the liver. We report the case of a 67-year-old woman with metastatic anal carcinoma to the liver who was successfully treated with liver resection and remains free of relapse more than one year later.
尽管罕见,但转移性肛管癌的预后很差。全身化疗是晚期疾病的主要治疗方法,而生物制剂和/或转移性疾病的手术切除作用尚无定论。与孤立性肝转移的结直肠癌或神经内分泌癌肝转移相比,对于肝转移的转移性肛管癌患者,手术切除或非手术局部消融治疗的经验要少得多。我们报告了一例67岁肝转移的转移性肛管癌女性患者,她接受肝切除术后成功治愈,一年多后仍未复发。